The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical trial
Background: The risk of coronary artery disease in people with high serum cholesterol is more than twice as high as in those with moderate serum cholesterol. Natural medicines, especially herbs, have been the focus of attention for many years because of the desirable and minimal side effects for con...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-02-01
|
| Series: | Phytomedicine Plus |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667031324001659 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823861204938915840 |
|---|---|
| author | Mahdi Badiee Gavarti Ali Askari Hamidreza Roohafza Mozhde Askari Zahra Teimouri Jervekani Shima Kaveh Mohammad Kermanialghoraishi Alireza Sadeghimahoonak Masoumeh Sadeghi |
| author_facet | Mahdi Badiee Gavarti Ali Askari Hamidreza Roohafza Mozhde Askari Zahra Teimouri Jervekani Shima Kaveh Mohammad Kermanialghoraishi Alireza Sadeghimahoonak Masoumeh Sadeghi |
| author_sort | Mahdi Badiee Gavarti |
| collection | DOAJ |
| description | Background: The risk of coronary artery disease in people with high serum cholesterol is more than twice as high as in those with moderate serum cholesterol. Natural medicines, especially herbs, have been the focus of attention for many years because of the desirable and minimal side effects for controlling blood lipids. Purpose: The present study aims to investigate the effect of fenugreek hydrolyzed protein (FHP) on lipid profile in patients with mild-to-moderate hypercholesterolemia. Methods: This study is a confirmatory, triple-blind, two-group parallel, randomized controlled trial, phase 3 conducted on patients aged 18–65 years with mild-to-moderate hypercholesterolemia and low risk for cardiovascular disease. Patients were recruited from a private clinic from May 2021 to June 2021. Sixty patients were randomized with a 1:1 allocation ratio into the FHP group (N = 30) and the placebo group (N = 30). The intervention group was administrated 40 mg/day of FHP for 8 weeks. Patients were examined at baseline and 8 weeks after randomization. The primary outcome was the patient's lipid profile including total cholesterol (TC), high-density lipoprotein (HDL-c), low-density lipoprotein (LDL-c), triglyceride (TG), and non-HDL-c. All participants, caregivers, outcome assessors, and analyzers were blind to the type of intervention. Results: In the intervention group, lipid profile improved through a significant reduction in TC (P < 0.001), LDL-c (P = 0.043), and non-HDL-c (P < 0.001), but no significant changes were observed in the TG level. The mean difference of these variables was -10.07 mg/dl [95 %CI:30.84; 10.70], -8.93 mg/dl [95 %CI:27.07; 9.21], and -10.37 mg/dl [95 %CI:32.26; 11.52] for TC, LDL-c, and non-HDL-c, respectively. FHP successfully decreased LDL-c level by 7 %. There was no significant change in any component of the lipid profile in the comparison group. FHP was well tolerated with only 1 patient experiencing gastrointestinal adverse manifestations. Conclusion: These findings suggest that FHP administration can improve the lipid profile of patients with mild-to-moderate hypercholesterolemia. Considering the low adverse effects of FHP and patients' high tolerance, it can be considered in the management of these patients, who fall into the low-risk cardiovascular disease category, adjuvant to the main therapies. Registration code: IRCT20210125050 142N1 |
| format | Article |
| id | doaj-art-aebf03844da0439ba620fa33e18fade1 |
| institution | Kabale University |
| issn | 2667-0313 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Phytomedicine Plus |
| spelling | doaj-art-aebf03844da0439ba620fa33e18fade12025-02-10T04:35:09ZengElsevierPhytomedicine Plus2667-03132025-02-0151100691The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical trialMahdi Badiee Gavarti0Ali Askari1Hamidreza Roohafza2Mozhde Askari3Zahra Teimouri Jervekani4Shima Kaveh5Mohammad Kermanialghoraishi6Alireza Sadeghimahoonak7Masoumeh Sadeghi8Student Research Committee, School of Medicine, Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranCardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranIsfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranCardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranCardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranFaculty of Food Science & Technology, Gorgan University of Agricultural Sciences and Natural Resources, Gorgan, IranInterventional Cardiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Food Science and Technology, Gorgan University of Agricultural Sciences, Gorgan, Iran; Corresponding author at: Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranCardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran; Corresponding author at: Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, IranBackground: The risk of coronary artery disease in people with high serum cholesterol is more than twice as high as in those with moderate serum cholesterol. Natural medicines, especially herbs, have been the focus of attention for many years because of the desirable and minimal side effects for controlling blood lipids. Purpose: The present study aims to investigate the effect of fenugreek hydrolyzed protein (FHP) on lipid profile in patients with mild-to-moderate hypercholesterolemia. Methods: This study is a confirmatory, triple-blind, two-group parallel, randomized controlled trial, phase 3 conducted on patients aged 18–65 years with mild-to-moderate hypercholesterolemia and low risk for cardiovascular disease. Patients were recruited from a private clinic from May 2021 to June 2021. Sixty patients were randomized with a 1:1 allocation ratio into the FHP group (N = 30) and the placebo group (N = 30). The intervention group was administrated 40 mg/day of FHP for 8 weeks. Patients were examined at baseline and 8 weeks after randomization. The primary outcome was the patient's lipid profile including total cholesterol (TC), high-density lipoprotein (HDL-c), low-density lipoprotein (LDL-c), triglyceride (TG), and non-HDL-c. All participants, caregivers, outcome assessors, and analyzers were blind to the type of intervention. Results: In the intervention group, lipid profile improved through a significant reduction in TC (P < 0.001), LDL-c (P = 0.043), and non-HDL-c (P < 0.001), but no significant changes were observed in the TG level. The mean difference of these variables was -10.07 mg/dl [95 %CI:30.84; 10.70], -8.93 mg/dl [95 %CI:27.07; 9.21], and -10.37 mg/dl [95 %CI:32.26; 11.52] for TC, LDL-c, and non-HDL-c, respectively. FHP successfully decreased LDL-c level by 7 %. There was no significant change in any component of the lipid profile in the comparison group. FHP was well tolerated with only 1 patient experiencing gastrointestinal adverse manifestations. Conclusion: These findings suggest that FHP administration can improve the lipid profile of patients with mild-to-moderate hypercholesterolemia. Considering the low adverse effects of FHP and patients' high tolerance, it can be considered in the management of these patients, who fall into the low-risk cardiovascular disease category, adjuvant to the main therapies. Registration code: IRCT20210125050 142N1http://www.sciencedirect.com/science/article/pii/S2667031324001659FenugreekHypercholesterolemiaBlood lipids |
| spellingShingle | Mahdi Badiee Gavarti Ali Askari Hamidreza Roohafza Mozhde Askari Zahra Teimouri Jervekani Shima Kaveh Mohammad Kermanialghoraishi Alireza Sadeghimahoonak Masoumeh Sadeghi The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical trial Phytomedicine Plus Fenugreek Hypercholesterolemia Blood lipids |
| title | The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical trial |
| title_full | The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical trial |
| title_fullStr | The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical trial |
| title_full_unstemmed | The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical trial |
| title_short | The effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild-to-moderate hypercholesterolemia: A confirmatory triple-blind randomized-controlled clinical trial |
| title_sort | effect of the fenugreek hydrolyzed protein on lipid profile in patients with mild to moderate hypercholesterolemia a confirmatory triple blind randomized controlled clinical trial |
| topic | Fenugreek Hypercholesterolemia Blood lipids |
| url | http://www.sciencedirect.com/science/article/pii/S2667031324001659 |
| work_keys_str_mv | AT mahdibadieegavarti theeffectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT aliaskari theeffectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT hamidrezaroohafza theeffectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT mozhdeaskari theeffectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT zahrateimourijervekani theeffectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT shimakaveh theeffectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT mohammadkermanialghoraishi theeffectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT alirezasadeghimahoonak theeffectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT masoumehsadeghi theeffectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT mahdibadieegavarti effectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT aliaskari effectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT hamidrezaroohafza effectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT mozhdeaskari effectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT zahrateimourijervekani effectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT shimakaveh effectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT mohammadkermanialghoraishi effectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT alirezasadeghimahoonak effectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial AT masoumehsadeghi effectofthefenugreekhydrolyzedproteinonlipidprofileinpatientswithmildtomoderatehypercholesterolemiaaconfirmatorytripleblindrandomizedcontrolledclinicaltrial |